Dermatology Doctors in Vestal, NY Accepting Medicare
8 Dermatology doctors found. Showing 1 - 8
 Dr. Colleen Mary Crandell, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 200 Plaza Dr, Suite B, Vestal, NY 13850 Phone: 607-729-2777 |
Manisha Manmohan, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 200 Front St, Vestal, NY 13850 Phone: 607-658-1003 Fax: 607-658-1006 |
 Romeo Morales, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 200 Front St, Vestal, NY 13850 Phone: 607-658-1003 Fax: 607-658-1006 |
Shelly Rivas, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3101 Shippers Rd Ste 102, Vestal, NY 13850 Phone: 607-251-2100 |
Ayyaz M Shah, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 200 Front St, Vestal, NY 13850 Phone: 607-658-1003 Fax: 607-658-1006 |
Dr. Uzoma Oranu, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 200 Front St, Vestal, NY 13850 Phone: 607-658-1003 Fax: 607-658-1006 |
Dr. Genadij Sienkiewicz, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 200 Front St, Vestal, NY 13850 Phone: 607-658-1003 Fax: 607-658-1006 |
Dr. Joseph M Newmark, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4104 Vestal Rd, Vestal Executive Park Suite 203, Vestal, NY 13850 Phone: 607-797-9036 Fax: 607-798-0601 |
News Archive
Vitrolife obtains Chinese SFDA approval for aspiration needles and micropipettes
Vitrolife has obtained regulatory approval from the Chinese SFDA (State Food and Drug Administration) for aspiration needles and micropipettes used for infertility treatment.
Pituitary adenoma predisposition caused by germline mutations in the AIP gene
A recent Finnish study identifies a low-penetrance gene defect which predisposes carriers to intracranial tumors called pituitary adenomas. In particular individuals carrying the gene defect are susceptible to such tumors which secrete growth hormone.
FDA grants priority review for Bayer HealthCare's riociguat for treatment of CTEPH
Bayer HealthCare announced today that the New Drug Application for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration for the treatment of inoperable chronic thromboembolic pulmonary hypertension or with persistent or recurrent CTEPH after pulmonary endarterectomy and pulmonary arterial hypertension.
Pilot Diode Laser launched by The CAO Group
The CAO Group, Inc., the world's top diode laser company, today unveiled the Pilot™ Diode Laser, an innovative surgical and therapeutic instrument that represents a breakthrough for veterinary surgical and therapeutic treatments.
GWAS suggests genetic variant with increased oncogene expression for cancer study
The study, published July 13th in Genome Research, showcases a new protocol for studying the activity of cancer-risk variants suggested by GWAS studies. The results also underscore the dramatic consequences of small genetic changes even in the vast stretches of DNA, known as "gene deserts," that do not code for proteins.
› Verified 1 days ago
Internal Medicine
Family Medicine
Psychiatry & Neurology
Dermatology
Obstetrics & Gynecology
Orthopaedic Surgery
Pediatrics
Physical Medicine & Rehabilitation
Surgery
Rheumatology